Sh pharma announced that the Apremilast tablets (specifications 10mg, 20mg, and 30mg) from its holding subsidiary Changzhou Pharmaceutical Factory received the "Pharmaceutical Registration Certificate" issued by the National Medical Products Administration, and the pharmaceutical has been approved for production. Apremilast tablets are primarily used for treating adult patients with moderate to severe plaque psoriasis. This pharmaceutical was developed by Celgene and was approved by the FDA for marketing in March 2014. In July 2023, Changzhou Pharmaceutical Factory submitted a registration application for this pharmaceutical to the National Medical Products Administration. As of the announcement date, the company has invested approximately 12.36049 million yuan in R&D expenses for this pharmaceutical. This production approval is beneficial for expanding the market share of this pharmaceutical and enhancing market competitiveness.